%0 Journal Article
%T Low-dose etomidate for the management of severe hypercortisolaemia in different clinical scenarios: a case series and review of the literature
%A Agnieszka £¿ebek-Szata¨½ska
%A Agnieszka £¿y£¿ka
%A El£¿bieta Baum
%A Karolina M. Nowak
%A Lucyna Papierska
%A Wojciech Zgliczy¨½ski
%J Archive of "Therapeutic Advances in Endocrinology and Metabolism".
%D 2019
%R 10.1177/2042018819825541
%X Severe Cushing¡¯s syndrome (SCS) is associated with acute cardiovascular, metabolic and infectious complications. It is considered an emergency, requiring an immediate diagnosis, together with a broad spectrum of supportive and hypocortisolaemic treatments. Surgical intervention, aimed at removing the source of cortisol or adrenocorticotropic hormone (ACTH), is the optimal treatment in most cases of Cushing¡¯s syndrome. However, in hypercortisolaemic states, surgical intervention has high rates of perioperative mortality and morbidity. Oral adrenal steroidogenesis inhibitors, even if more effective in combination, are not always efficient enough or well tolerated. Despite their common use, a more potent, parental, immediate, and thus life-saving, therapy is necessary
%K adrenal steroidogenesis inhibitors
%K adrenocortical carcinoma
%K Cushing¡¯s disease
%K ectopic Cushing¡¯s syndrome
%K etomidate
%K hypercortisolaemia
%K pituitary corticotropinoma
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378481/